Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Baxter

This article was originally published in The Gray Sheet

  • News

Executive Summary

Acquisition of North American Vaccine announced Nov. 15 is valued at about $390 mil. The company has offered $7 per share, $6.97 in Baxter common stock and $0.03 cash for the 37 mil. shares of NAVA stock outstanding. Baxter also will assume $133 mil. in debt. In addition, BioChem Pharma has agreed to sell its 13.2-mil. share stake in NAVA to Baxter. Those shares are worth roughly $92 mil. under the deal, which brings NAVA's bacterial vaccine experience to Baxter's viral vaccine expertise. In addition, Baxter announces that CEO Harry Kraemer will assume the additional title of chairman following the retirement of Vernon Loucks on Dec. 31

Table

View full table

Tags:
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT012593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By